HOME >> BIOLOGY >> NEWS
Malignant breast cancer cells to revert to normal with manipulation

Speaking at Experimental Biology 2004, Dr. Mina Bissell describes research showing how manipulation of the extracellular matrix (a network of fibrous and globular proteins that surrounds breast cells) of non-malignant breast cells can lead to genomic instability via oxidative damage. She describes how manipulation of the microenvironment can allow malignant breast cancer cells to revert to normal cells again. She also describes how the tissue culture of the extracellular matrix affects the cancerous cells' resistance to chemotherapy, independently of the characteristics of the malignancy itself.

Her presentation is part of the scientific program of the American Association of Anatomists, one of the six sponsoring societies of this year's Experimental Biology meeting.

Dr. Bissell, a Distinguished Scientist at the Lawrence Berkeley Laboratory, is best known as the researcher who uncovered the critical role of extracellular matrix (ECM) in normal breast function and how its aberration may contribute to breast cancer development. While the role of ECM during embryonic development had been recognized for decades, its important role in tissue-specific function was not appreciated before the work in a handful of laboratories including Dr. Bissell's laboratory. In fact, ECM was regarded as scaffolding for tissues and not much more.

Dr. Bissell postulated in 1981, and later showed experimentally, that the ECM was part of a "dynamic reciprocity" in the social interaction between cells and the nucleus much like hormones and growth factors, with the ECM at times telling the nucleus of the cells what to do and thus directing gene expression in conjunction with these other factors. She had chosen the breast to study the critical role of the ECM in normal breast tissue, a model she had selected because it continues to change throughout life of women in puberty, pregnancy, lactation, and once breast feeding is done (involution). In some of their earliest
'"/>

Contact: Sarah Goodwin
eb4press@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
18-Apr-2004


Page: 1 2 3

Related biology news :

1. Malignant cancer cells generate mice through cloning
2. Certain genes boost fish oils protection against breast cancer
3. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
4. Progress in breast cancer progression
5. The telomere crisis: A crucial stage in breast cancer
6. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
7. More aggressive breast cancer tumors found in African American women
8. Alterations in vitamin D receptor gene increase prostate, breast cancer risk
9. Study links high carbohydrate diet to increased breast cancer risk
10. UCI study reveals gene linked to breast cancer can suppress tumors
11. Animal research suggests plant estrogens in soy do not increase breast cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ... oral peptide drug candidates, PTG-100 and PTG-200, at ... Crohn,s and Colitis Organization (ECCO).  The ECCO congress ... from February 15 – 18, 2017. ... on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
Cached News: